The effect of creatine and coenzyme Q10 combination therapy on mild cognitive impairment in parkinson's disease

European Neurology

Volumn 73, Issue 3-4, 2015, Pages 205-211

  Li, Zhenguang ^a   Wang, Pengfei ^a   Yu, Zhancai ^a   Cong, Yannan ^a   Sun, Hairong ^a   Zhang, Jiangshan ^a   Zhang, Jinbiao ^a   Sun, Chao ^a   Zhang, Yong ^a   Ju, Xiaohua ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Coenzyme Q10; Creatine; Mild cognitive impairment; Parkinson's disease; Phospholipids

Indexed keywords

CREATINE; PHOSPHOLIPID; PLACEBO; UBIDECARENONE; UBIQUINONE;

ADULT; AGED; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MONTREAL COGNITIVE ASSESSMENT; PARKINSON DISEASE; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGED; COGNITION; CREATINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE; UBIQUINONE;

EID: 84925440145     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000377676     Document Type: Article

References (36)

1. Kones R: Mitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifying. Clin Pharmacol 2010; 2: 185-198.
2. Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF: Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem 2009; 109: 1427-1439.
3. Litvan I, Goldman JG, Tröster AI, et al: Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement disorder society task force guidelines. Mov Disord 2012; 27: 349-356.
4. Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM: Measuring disease progression in early Parkinson disease: the national institutes of health exploratory trials in Parkinson disease (NET-PD) experience. JAMA Neurol 2014; 71: 710-716.
5. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H: The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-699.
6. Memória CM, Yassuda MS, Nakano EY, Forlenza OV: Brief screening for mild cognitive impairment: validation of the Brazilian version of the montreal cognitive assessment. Int J Geriatr Psychiatry 2013; 28: 34-40.
7. Hu MT, Szewczyk-Królikowski K, Tomlinson P, Nithi K, Rolinski M, Murray C, Talbot K, Ebmeier KP, Mackay CE, Ben-Shlomo Y: Predictors of cognitive impairment in an early stage Parkinson's disease cohort. Mov Disord 2014; 29: 351-359.
8. Ng A, Chew I, Narasimhalu K, Kandiah N: Effectiveness of montreal cognitive assessment for the diagnosis of mild cognitive impairment and mild Alzheimer's disease in Singapore. Singapore Med J 2013; 54: 616-619.
9. Zhou S, Zhu J, Zhang N, Wang B, Li T, Lv X, Ng TP, Yu X, Wang H: The influence of education on Chinese version of montreal cognitive assessment in detecting amnesic mild cognitive impairment among older people in a Beijing rural community. ScientificWorld-Journal 2014; 2014: 689456.
10. Goldman JG, Litvan I: Mild cognitive impairment in Parkinson's disease. Minerva Med 2011; 102: 441-459.
11. Jellinger K: Heterogenous mechanisms of mild cognitive impairment in Parkinson's disease. J Neural Transm 2012; 119: 381-382.
12. Dolder M, Walzel B, Speer O, Schlattner U, Wallimann T: Inhibition of the mitochondrial permeability transition by creatine kinase substrates. Requirement for microcompartmentation. J Biol Chem 2003; 278: 17760-17766.
13. Beal MF: Neuroprotective effects of creatine. Amino Acids 2011; 40: 1305-1313.
14. Prass K, Royl G, Lindauer U, Freyer D, Megow D, Dirnagl U, Stockler-Ipsiroglu G, Wallimann T, Priller J: Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J Cereb Blood Flow Metab 2007; 27: 452-459.
15. Couzin J: Clinical research. Testing a novel strategy against Parkinson's disease. Science 2007; 315: 1778.
16. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF: Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999; 157: 142-149.
17. Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, Gekeler F, Müller-Myhsok B, Gasser T, Tatsch K, Klopstock T: Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006; 67: 1262-1264.
18. NINDS NET-PD Investigators: A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006; 66: 664-671.
19. Kones R: Mitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifying. Clin Pharmacol 2010; 2: 185-198.
20. Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF: Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem 2009; 109: 1427-1439.
21. Litvan I, Goldman JG, Tröster AI, et al: Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement disorder society task force guidelines. Mov Disord 2012; 27: 349-356.
22. Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM: Measuring disease progression in early Parkinson disease: the national institutes of health exploratory trials in Parkinson disease (NET-PD) experience. JAMA Neurol 2014; 71: 710-716.
23. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H: The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-699.
24. Memória CM, Yassuda MS, Nakano EY, Forlenza OV: Brief screening for mild cognitive impairment: validation of the Brazilian version of the montreal cognitive assessment. Int J Geriatr Psychiatry 2013; 28: 34-40.
25. Hu MT, Szewczyk-Królikowski K, Tomlinson P, Nithi K, Rolinski M, Murray C, Talbot K, Ebmeier KP, Mackay CE, Ben-Shlomo Y: Predictors of cognitive impairment in an early stage Parkinson's disease cohort. Mov Disord 2014; 29: 351-359.
26. Ng A, Chew I, Narasimhalu K, Kandiah N: Effectiveness of montreal cognitive assessment for the diagnosis of mild cognitive impairment and mild Alzheimer's disease in Singapore. Singapore Med J 2013; 54: 616-619.
27. Zhou S, Zhu J, Zhang N, Wang B, Li T, Lv X, Ng TP, Yu X, Wang H: The influence of education on Chinese version of montreal cognitive assessment in detecting amnesic mild cognitive impairment among older people in a Beijing rural community. ScientificWorld-Journal 2014; 2014: 689456.
28. Goldman JG, Litvan I: Mild cognitive impairment in Parkinson's disease. Minerva Med 2011; 102: 441-459.
29. Jellinger K: Heterogenous mechanisms of mild cognitive impairment in Parkinson's disease. J Neural Transm 2012; 119: 381-382.
30. Dolder M, Walzel B, Speer O, Schlattner U, Wallimann T: Inhibition of the mitochondrial permeability transition by creatine kinase substrates. Requirement for microcompartmentation. J Biol Chem 2003; 278: 17760-17766.
31. Beal MF: Neuroprotective effects of creatine. Amino Acids 2011; 40: 1305-1313.
32. Prass K, Royl G, Lindauer U, Freyer D, Megow D, Dirnagl U, Stockler-Ipsiroglu G, Wallimann T, Priller J: Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J Cereb Blood Flow Metab 2007; 27: 452-459.
33. Couzin J: Clinical research. Testing a novel strategy against Parkinson's disease. Science 2007; 315: 1778.
34. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF: Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999; 157: 142-149.
35. Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, Gekeler F, Müller-Myhsok B, Gasser T, Tatsch K, Klopstock T: Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006; 67: 1262-1264.
36. NINDS NET-PD Investigators: A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006; 66: 664-671.